After executing a significant IP sale, Bigfoot Biomedical looks to double down on its diabetes management platform. Less than two years ago, Bigfoot Biomedical launched its Bigfoot Unity platform in some U.S. states. CEO Jeffrey Brewer last year called it a “transformational attempt” to simplify CGMs and the data they produce. It features a smart […]
Diabetes
FDA clears Abbott FreeStyle Libre for automated insulin pump integration
Abbott (NYSE:ABT) announced today that the FDA cleared its FreeStyle Libre 2 and FreeStyle Libre 3 for automated insulin delivery (AID) integration. AID systems help people manage daily diabetes care by automatically adjusting and administering the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre […]
Expanded Medicare coverage for CGM to go into effect next month
The Centers for Medicare & Medicaid Services today published a final local coverage determination (LCD) expanding coverage for CGMs. New, expanded coverage of continuous glucose monitors (CGMs) under Medicare go into effect in April. CMS first published the LCD modifying coverage criteria for CGMs in October. The modification includes people with diabetes who receive insulin […]
Bigfoot Biomedical wins FDA clearance for Bigfoot Unity Android app
Bigfoot Biomedical announced today that it received FDA 510(k) clearance for the Android version of its Bigfoot Unity mobile app. Milpitas, California-based Bigfoot received FDA clearance for its diabetes management platform in May 2021. Its initial rollout featured compatibility with iOS devices. The first-of-its-kind system includes connected smart pen caps designed to recommend insulin doses […]
Vivani Medical wants to bring a subdermal drug delivery implant to the diabetes market
Where some have tried and failed, Vivani Medical believes its drug-delivering implants can go the distance. When Second Sight Medical and Nano Precision Medical merged last year, the rebranded company — Vivani Medical (Nasdaq:VANI)— had a goal: bring a six-month, subdermal drug delivery implant that treats conditions including type 2 diabetes to market. CEO Dr. […]
Eli Lilly is cutting the price of insulin by 70%
Eli Lilly (NYSE:LLY) announced today that it plans to execute price reductions of 70% for its most commonly prescribed insulins. Indianapolis-based Lilly also plans to expand its Insulin Value Program. This caps patient out-of-pocket costs at $35 or less per month. The company said it took these actions to “help Americans” in a “complex healthcare […]
Tandem Diabetes Care appoints new board chair
Tandem Diabetes Care (Nasdaq:TNDM) recently announced the appointment of Rebecca Robertson as the chair of its board of directors. Robertson initially joined Tandem’s board as an independent director in January 2019. She succeeds Kim Blickenstaff as chair. Blickenstaff intends to continue as a member of the board. “We’re deeply grateful to Kim for his instrumental […]
Study backs Medtronic next-gen MiniMed 780G insulin pump for type 1 diabetes
Medtronic (NYSE:MDT) announced today that one-year data backs the use of its next-generation MiniMed 780G automated insulin pump. The ADAPT study compared MiniMed 780 G against multiple daily injections of insulin with an intermittently scanned CGM. ADAPT, which included 82 subjects, marks the first multi-national, randomized controlled study comparing these methods. The study evaluated adults […]
Insulet stock rises on Street-beating Q4, expected Omnipod growth
Insulet (Nasdaq:PODD) shares ticked up today — a day after releasing fourth-quarter results that came in well ahead of the consensus forecast. Shares of PODD were up slightly to $299.29 apiece by midday trading today. The Acton, Massachusetts-based automated insulin technology developer posted profits of $17 million. That amounts to 24¢ per share on sales […]
Report: Apple moves forward with glucose monitoring tech
Apple reportedly believes it could shake up the CGM market with non-invasive glucose monitoring through the Apple Watch. Blooomberg reported that the company has a “moonshot-style” project in the works, according to “sources familiar with the matter.” The report said the tech giant still has years ahead in this development of the technology, which wouldn’t […]